Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(4):270-274
DOI: 10.5428/pcar20170408
Comparisons of the efficacy and safety between ulinastatin and gabexate in acute pancreatitis and post-endoscopic retrograde cholangiopancreatography pancreatitis:a meta review
1. HUANG WenHui(Department of Pharmacy,No.175 Hospital of PLA,Fujian Zhangzhou 363000,China hwhui175@163.com)
2. ZHANG YunChen(Department of Pharmacy,No.175 Hospital of PLA,Fujian Zhangzhou 363000,China )
3. ZHAN ZhiHong(Department of Pharmacy,No.175 Hospital of PLA,Fujian Zhangzhou 363000,China )
4. FEI Yan(Department of Pharmacy,No.175 Hospital of PLA,Fujian Zhangzhou 363000,China feiyanfy@126.com)
ABSTRACT  Objective: To compare the efficacy and safety of ulinastatin and gabexate in acute pancreatitis and post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis.Methods: The databases of the Cochrane Library,PubMed,the Chinese Science and Technology Journal Database(Chongqing VIP),the Chinese Biomedical Literature Database (CBM),the Chinese Journal Full-text Database in China National Knowledge Infrastructure(CNKI),Online library(Wiley-Blackwell,Science and Springer Link,Elsevier Science-Science Direct) were searched(till September 2016) for related literature.The randomized controlled trials(RCTs) that met the inclusion criteria were collected and the quality of included RCTs was assessed according to the Cochrane Collaboration system review,and then meta analysis was performed using RevMan 5.3 software.Results: A total of 6 papers concerning RCTs were included in the study.Meta analysis indicated that the efficiency rate,abdominal tenderness remission rate and main symptom remission rate for the acute pancreatitis patients of the ulinastatin group were higher than those of the gabexate group[efficiency: odds ratio (OR) =2.52,95%CI 1.54-4.12,P=0.000 2; rate of abdominal tenderness disappearance:OR=15.01,95%CI 1.97-114.57,P=0.009; main symptom remission rate:OR=2.59,95%CI 1.33-5.07,P=0.005],and the rate of adverse drug reactions was lower in the ulinastatin group than that in the gabexate group.The ulinastatin group and the gabexate group were similar in the incidence of pancreatitis and hyperamylasemia in post-ERCP pancreatitis patients(post-ERCP pancreatitis incidence:OR=1.57,95%CI 0.39-6.24,P=0.52;hyperamylasemia incidence:OR=1.85,95%CI 0.83-4.13,P=0.13).The two groups were not significantly different in the incidence of adverse drug reactions.Conclusion: Ulinastatin was better and safer than gabexate in the treatment of acute pancreatitis.However,the two drugs were similar in efficacy and safety in the prevention of post-ERCP pancreatitis.High-quality and large-sample randomized controlled trials were required for the confirmation of long-term safety.
Welcome to PCAR! You are the number 59 reader of this article!
Please cite this article as:
HUANG WenHui,ZHANG YunChen,ZHAN ZhiHong,FEI Yan,. Comparisons of the efficacy and safety between ulinastatin and gabexate in acute pancreatitis and post-endoscopic retrograde cholangiopancreatography pancreatitis:a meta review[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(4): 270-274.
References:
1. Pancreatopathy Group,Branch of Digestion,Chinese Medical Associaton,Editorial Board of Chinese Journal of Pancreatopathy,Editorial Board of Chinese Journal of Digestion.Diagnosis and treatment guidelines for acute pancreatitis in China(2013,Shanghai)[J].Chin J Pract Intern Med,2013,33(7):530-535.In Chinese.
2. WANG HuaHong,HU FuLian,LIN SanRen,et al.The efficacy and safety of domestic ulinastatin in the treatment of acute pancreatitis[J].Chin J New Drugs,2001,10(3):204-206.In Chinese with English abstract.
3. PEI JiHua.Clinical observation on treatment of acute pancreatitis with domestic ulinastatin[D].Changchun:Jilin Univ,2004.In Chinese with English abstract.
4. SONG ZhengWei,WANG HongLin.Risk factors and prevention of complications associated with endoscopic retrograde cholangiopancreatography[J].Lab Med Clin,2010,7(7):660-662.In Chinese.
5. ZHANG Jun,LI Fei.Role of gabexate mesylate in prevention of post-ERCP pancreatitis:a meta analysis[J].Chin J Bases Clin General Surg,2012,19(1):48-57.In Chinese with English abstract.
6. Pancreatopathy Group,Society of Surgery,Chinese Medical Association.Clinical diagnosis and grading criteria of acute pancreatitis (1996,the 2nd protocol)[J].Chin J Surg,1997,35(12):773-776.In Chinese.
7. Cotton P B,Lehman G,Vennes J,et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc,1991,37(3):383-393.
8. The Cochrane Collaboration.Cochrane handbook for systematic reviews of interventions version 5.1.0[EB/OL].(2011-03)[2016-02-29].http://handbook.cochrane.org/.
9. LI Dan.Efficacy of ulinastatin in the treatment of acute edematous pancreatitis[J].J Guangdong Med Coll,2003,21(5):482-483.In Chinese.
10. XUAN XuJie,GONG Wei,ZHANG LianJu.Clinical efficacy of ulinastatin in the treatment of acute pancreatitis[J].Cent Plains Med J,2006,33(13):68-69.In Chinese.
11. Fujishiro H,Adachi K,Imaoka T,et al.Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study[J].J Gastroenterol Hepatol,2006,21(6):1065-1069.
12. Ueki T,Otani K,Kawamoto K,et al.Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:a prospective,randomized trial[J].J Gastroenterol,2007,42(2):161-167.
13. Shanghai Collaboration Group on Ulinastatin Clinical Trials.Multi-center clinical trial on the treatment of acute pancreatitis by ulinastatin[J].Chin J Dig,2001,21(5):293-296.In Chinese with English abstract.
14. XIONG GuangSu,ZHANG XiWen,WU ShuMing,et al.Prophylactic effect of gabexate on post-ERCP pancreatitis:a clinical observation[J].Chin J Pancreatol,2001,5(4):200-202.In Chinese with English abstract.
15. PING Xun.Comparison of the efficacy of ulinastatin and gabexate in the treatment of acute mild pancreatitis[J].Shandong Med Pharm J,2006,46(4):31.In Chinese.
16. GONG Peng,WANG ZhongYu,TAI PengJun,et al.Prevention and treatment for post ERCP pancreatitis[J].J Hepatobiliary Surg,2004,12(2):101-103.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口